Semaglutide Side Effects: The Definitive Guide

Semaglutide's most common side effects are gastrointestinal: in the pivotal STEP 1 weight-management trial, nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) were far more frequent than with placebo. Most are mild-to-moderate and concentrate during dose escalation. Serious risks — pancreatitis, gallbladder disease, and a thyroid-tumor boxed warning — are rarer.

Semaglutide side effects at a glance

• Drug class: GLP-1 receptor agonist (peptide analog of human GLP-1)
• Brand names: Ozempic, Rybelsus (type 2 diabetes); Wegovy (chronic weight management)
• Most common side effects: nausea, diarrhea, vomiting, constipation, abdominal pain
• When they peak: during the 16-week dose-escalation period to the 2.4 mg maintenance dose
• Serious but rarer risks: acute pancreatitis, acute gallbladder disease, acute kidney injury (from dehydration)
• Boxed warning: thyroid C-cell tumors (rodent data); contraindicated with personal/family history of medullary thyroid carcinoma (MTC) or MEN 2
• FDA status: approved (Ozempic 2017, Wegovy 2021); compounded versions face tightening 2026 restrictions

What are the most common semaglutide side effects?

The most common semaglutide side effects are gastrointestinal. In the STEP 1 trial — a 68-week, randomized, double-blind study of 1,961 adults with overweight or obesity — gastrointestinal disorders affected 74.2% of the semaglutide group versus 47.9% of the placebo group (Wilding et al., 2021, N Engl J Med).

The FDA label for Wegovy (semaglutide 2.4 mg) reports the following adverse-reaction rates versus placebo:

These figures come from the FDA-approved Wegovy prescribing information (FDA, 2026). Most events were mild-to-moderate and resolved over time. A real-world analysis of the FDA Adverse Event Reporting System (FAERS) reviewed 5,442 semaglutide-associated gastrointestinal reports and found nausea, vomiting, diarrhea, and constipation were the most frequently reported events (Shu et al., 2022, Front Public Health).

Other reported reactions include fatigue, headache, dizziness, belching, and a reduced appetite (often the intended effect, though it can become uncomfortable). Consult your healthcare provider before starting any peptide protocol.

Why does semaglutide cause nausea and stomach problems?

Semaglutide is a GLP-1 receptor agonist. By activating GLP-1 receptors, it slows gastric emptying — food leaves the stomach more slowly — and acts on appetite centers in the brain. That delayed emptying is part of how the drug reduces appetite and food intake, but it is also the main driver of nausea, fullness, and vomiting.

Because the body adapts to this effect over time, side effects are typically worst when the dose increases. The FAERS pharmacovigilance analysis and the trial data both point to dose escalation as the highest-risk window (Shu et al., 2022, Front Public Health). This is why standard protocols start at a low dose and step up gradually over roughly 16 weeks rather than starting at the full 2.4 mg maintenance dose.

In clinical practice, slower titration, smaller meals, avoiding high-fat or greasy foods, and adequate hydration are commonly cited strategies for reducing gastrointestinal symptoms — but you should discuss any dose adjustment with your healthcare provider rather than changing it yourself.

How long do semaglutide side effects last?

For most people, gastrointestinal side effects are concentrated in the early weeks and during each dose increase, then ease as the body adapts. In the trials, the most pronounced nausea and vomiting clustered around the dose-escalation phase to the 2.4 mg maintenance dose.

Side effects that persist, worsen, or appear suddenly after a stable period are different and warrant medical attention — they can signal a more serious problem such as pancreatitis or gallbladder disease (see below). There is no fixed timeline that fits everyone; individual response varies widely. Consult your healthcare provider if symptoms are not improving or are interfering with eating and hydration.

What are the serious side effects of semaglutide?

Most semaglutide side effects are mild, but several serious risks appear in the FDA label's Warnings and Precautions and require prompt medical attention.

Acute pancreatitis. The label warns of acute pancreatitis (including fatal cases reported with GLP-1 drugs). Notably, a meta-analysis of randomized trials did not find a statistically significant increase in pancreatitis with semaglutide versus placebo, so the absolute risk appears low — but the warning remains, and severe, persistent abdominal pain radiating to the back is a red flag.

Acute gallbladder disease. GLP-1 receptor agonist use was associated with an increased risk of gallbladder and biliary disease in a meta-analysis of 76 randomized trials covering 103,371 participants, with a relative risk of 1.37 (95% CI, 1.23–1.52); risk was higher at higher doses, longer durations, and when used for weight loss (He et al., 2022, JAMA Intern Med). Rapid weight loss itself promotes gallstones.

Acute kidney injury. The label notes postmarketing reports of acute kidney injury, sometimes requiring dialysis, mostly in patients who became dehydrated from nausea, vomiting, or diarrhea (FDA, 2026).

Severe gastrointestinal reactions and ileus. Severe constipation, intestinal obstruction, and ileus have been reported.

Other labeled warnings include hypoglycemia (especially when combined with insulin or sulfonylureas), serious hypersensitivity reactions, diabetic retinopathy complications in people with type 2 diabetes, increased heart rate, and a risk of retained gastric contents (pulmonary aspiration) during anesthesia or deep sedation.

Seek emergency care for severe abdominal pain, persistent vomiting, signs of an allergic reaction, or symptoms of dehydration. Consult your healthcare provider before starting any peptide protocol.

Does semaglutide cause thyroid cancer? Understanding the boxed warning

Semaglutide carries an FDA boxed warning — the agency's strongest — for thyroid C-cell tumors. The basis is preclinical: in rodents, semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures.

Critically, the label states it is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, because the human relevance of the rodent findings has not been determined (FDA, 2026). Human data have not established a causal link.

Because of this uncertainty, semaglutide is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also contraindicated in anyone with a prior serious hypersensitivity reaction to semaglutide. This is a clear example of a warning that targets a specific high-risk group rather than implying broad population risk. If you have a family history of thyroid cancer or endocrine tumors, raise it with your healthcare provider before considering any GLP-1 medication.

Are compounded semaglutide side effects different?

The active ingredient should behave the same, but the risk profile around compounded semaglutide is different — and the regulatory ground is shifting fast in 2026.

The FDA resolved the semaglutide shortage in early 2025, which removed the legal basis for most large-scale compounding. The agency has since clarified that compounding a product that is "essentially a copy" of an FDA-approved drug is impermissible for both 503A pharmacies and 503B outsourcing facilities, absent narrow exceptions (such as a documented excipient allergy or a strength not commercially available). On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List, finding no clinical need for outsourcing-facility compounding from bulk substances now that the shortage has ended; the public comment docket runs through June 29, 2026 (FDA, 2026).

The practical safety concern: compounded products are not FDA-reviewed for that specific formulation, and the FDA has separately warned about dosing errors with compounded injectable semaglutide. Salt forms (semaglutide sodium, semaglutide acetate) sold by some sellers are not the same as the FDA-approved active ingredient. Legal status varies by jurisdiction; consult a lawyer for binding advice, and consult your healthcare provider before using any compounded product.

How can semaglutide side effects be reduced?

Strategies commonly cited in clinical practice and the prescribing information focus on the dose-escalation period, when side effects peak:

• Gradual titration. Standard protocols step the dose up slowly over ~16 weeks rather than starting high. Any change to the schedule should be provider-directed.
• Eating smaller, more frequent meals and stopping at first fullness, since gastric emptying is slowed.
• Limiting greasy, fried, and very high-fat foods, which tend to worsen nausea.
• Staying hydrated, which also lowers the dehydration-related kidney-injury risk noted in the label.
• Reporting red-flag symptoms early — severe abdominal pain, persistent vomiting, or signs of an allergic reaction.

These are general educational strategies, not a prescription. Dosing should be personalized with a provider, and you should consult your healthcare provider before starting, stopping, or adjusting any peptide protocol.

Frequently asked questions

Q: What is the most common side effect of semaglutide? A: Nausea is the single most common side effect. In the FDA-approved Wegovy prescribing information, nausea occurred in 44% of patients on semaglutide 2.4 mg versus 16% on placebo. It is usually mild-to-moderate, peaks during dose escalation, and tends to ease as the body adapts. Diarrhea (30%), vomiting (24%), and constipation (24%) follow. Persistent or severe symptoms should be discussed with a healthcare provider.

Q: Does semaglutide cause weight-related side effects beyond the stomach? A: Yes. Reported reactions include fatigue, headache, dizziness, and increased heart rate. Rapid weight loss can also raise the risk of gallstones — a meta-analysis of 76 randomized trials linked GLP-1 receptor agonists to a higher risk of gallbladder and biliary disease (relative risk 1.37), especially at higher doses and when used for weight loss (He et al., 2022, JAMA Intern Med). Consult your healthcare provider about monitoring.

Q: Is semaglutide safe long-term? A: Long-term data are accumulating. The SELECT cardiovascular outcomes trial followed adults for a mean of about 40 months and found semaglutide reduced major cardiovascular events versus placebo; gastrointestinal side effects were the leading reason for discontinuation, occurring in 16.6% of the semaglutide group versus 8.2% on placebo (Lincoff et al., 2023, N Engl J Med). Safety should be monitored over time by your healthcare provider.

Q: Who should not take semaglutide? A: Per the FDA label, semaglutide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in anyone with a prior serious hypersensitivity reaction to it. People with a history of pancreatitis or gallbladder disease should discuss the risks carefully with their healthcare provider before considering it.

Q: Can semaglutide cause pancreatitis? A: The FDA label warns of acute pancreatitis, and there have been reports including fatal cases with GLP-1 drugs. However, a meta-analysis of randomized trials did not find a statistically significant increase in acute pancreatitis with semaglutide versus placebo, suggesting the absolute risk is low. Severe abdominal pain radiating to the back is a red flag — seek medical care promptly. Consult your healthcare provider.

Q: When are semaglutide side effects the worst? A: Side effects are generally worst during the dose-escalation period — roughly the first 16 weeks while the dose steps up to the 2.4 mg maintenance level — and around each individual dose increase. Both the trial data and an FDA Adverse Event Reporting System analysis point to escalation as the highest-risk window (Shu et al., 2022, Front Public Health). Symptoms typically ease as the body adapts.

Q: Are compounded semaglutide side effects different from Ozempic or Wegovy? A: The active ingredient should act the same, but compounded products are not FDA-reviewed for that specific formulation, and the FDA has warned about dosing errors with compounded injectable semaglutide. Some sellers offer salt forms (semaglutide sodium or acetate) that differ from the approved active ingredient. As of 2026, the FDA has sharply restricted compounding now that the shortage has ended. Consult your healthcare provider.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185 · doi:10.1056/NEJMoa2032183
2. U.S. Food and Drug Administration. WEGOVY (semaglutide) injection — Highlights of Prescribing Information (boxed warning, contraindications, adverse reactions, warnings and precautions). 2026. DailyMed label
3. He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022;182(5):513-519. PMID: 35344001 · doi:10.1001/jamainternmed.2022.0338
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131 · doi:10.1056/NEJMoa2307563
5. Shu Y, He X, Wu P, et al. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022;10:996496. PMID: 36339230 · PMCID: PMC9631444
6. U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on the 503B Bulks List. April 30, 2026. FDA press announcement